Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40, is a matricellular protein involved in several biological processes including cell adhesion, growth factor availability, extracellular matrix remodeling and immune-regulation. SPARC has also been associated with a variety of diseases including diabetes, colon cancer, and leukemia. The expression of SPARC in different diseases exhibits some degree of ambiguity, especially in hemopathies. Herein, we review the current expression and effects of SPARC in various hematologic disorders with respect to nanoparticle albumin bound innovative therapies and related diagnostic research, providing a clinical perspective on the use of NAB technology in the frontier treatment of hematologic diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2022.113519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychometric Validation of Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients.
Cancer Res Treat
December 2024
Research Institute for Future Medical Science, Chungnam National University Sejong Hospital, Sejong, Korea.
Purpose: Identifying the palliative care needs of patients with advanced cancer is important for maintaining quality of life and timely transition to palliative care. We aimed to validate the Korean Sheffield Profile for Assessment and Referral for Care (K-SPARC) in such patients and establish its psychometric properties, including reliability, validity, and responsiveness to change.
Materials And Methods: We used the forward-back translated version of SPARC, which was verified through a pilot study, to assess the palliative care needs of patients with advanced cancer.
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model.
EJNMMI Res
November 2024
Quibim, Quantitative Imaging Biomarkers in Medicine, Av. d'Aragó, 30, Planta 13, 46021, Valencia, Spain.
Article Synopsis
- This study aims to create predictive models for treatment outcomes in patients with relapsed/refractory B-cell lymphoma undergoing CAR-T therapy by analyzing imaging data and clinical information.
- It includes a cohort of 65 patients, utilizing imaging features from PET/CT scans to assess treatment response, overall survival, progression-free survival, and neurotoxicity risk associated with the therapy.
- The results demonstrated that combining imaging features with clinical data significantly enhances prediction accuracy for treatment-related outcomes, highlighting the importance of metabolic tumor volume (MTV) in stratifying patient prognosis.
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.
Nat Cancer
December 2024
Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA.
Despite the abundance of somatic structural variations (SVs) in cancer, the underlying molecular mechanisms of their formation remain unclear. In the present study, we used 6,193 whole-genome sequenced tumors to study the contributions of transcription and DNA replication collisions to genome instability. After deconvoluting robust SV signatures in three independent pan-cancer cohorts, we detected transcription-dependent, replicated-strand bias, the expected footprint of transcription-replication collision (TRC), in large tandem duplications (TDs).
View Article and Find Full Text PDFThe epithelial barrier theory and its associated diseases.
Allergy
December 2024
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide.
View Article and Find Full Text PDFSynthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
Clin Cancer Res
December 2024
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Purpose: The cyclin-dependent kinase (CDK), CDK12, is mutated or amplified in multiple cancers. We previously described a subtype of prostate cancer characterized predominantly by frameshift, loss-of-function mutations in CDK12. This subtype exhibits aggressive clinical features.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!